Description
Klow Blend 110 is the higher-dosed version of Klow Blend. Each vial contains 110mg of active compounds: 50mg GHK-Cu, 20mg BPC-157, 20mg TB-500 (Thymosin Beta-4) and 20mg KPV. Compared to the regular Klow Blend (80mg: 50mg GHK-Cu plus 10mg each of BPC-157, TB-500 and KPV), the amount of the three peptide components doubles while the GHK-Cu content stays the same.
As with Klow Blend, the formulation addresses four complementary pathways at once: tissue repair and angiogenesis (BPC-157), cellular migration and stem cell mobilization (TB-500), collagen synthesis and microcirculation (GHK-Cu) and anti-inflammatory modulation (KPV). KPV is the C-terminal tripeptide of the alpha-MSH molecule and acts in research models through inhibition of pro-inflammatory transcription factors like NF-kB.
The difference is the ratio. In the regular Klow Blend, GHK-Cu makes up just over 60 percent of the vial content, in Klow Blend 110 it is around 45 percent. For research setups focused on BPC-157, TB-500 and KPV, one vial delivers twice as much of these three components without scaling up the copper component.
The advantage of the pre-mixed blend remains: four compounds, one reconstitution step, defined ratio.
Klow Blend 110 is available in 110mg vials as 10-vial packs. One pack contains 1.1 g of active compounds: 500mg GHK-Cu and 200mg each of BPC-157, TB-500 and KPV.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Klow Blend 110 contains the same four components as Klow Blend, each with a mild profile in the preclinical literature. For this exact ratio with twice the BPC-157, TB-500 and KPV, however, the data is even thinner than for the separate peptides.
Observed in research and user reports:
- Injection site: mild redness, pressure or transient irritation at the injection site is the most common observation with subcutaneous use.
- Copper component: the GHK-Cu component can cause somewhat more pronounced local irritation at the injection site than pure peptide solutions.
- Angiogenesis effect of the TB-500 component: because TB-500 promotes the formation of new blood vessels in studies, a theoretical concern is discussed that existing abnormal tissue could also be supplied. No evidence supports this.
- No long-term data: robust long-term human studies do not exist for any of the four components.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing - Cell and Tissue Research 2019: Critical review of the BPC-157 component in tendon, ligament and muscle models: consistently positive findings, but almost exclusively from rodent studies, with confirmation in humans still pending.
- Thymosin beta4 accelerates wound healing - Journal of Investigative Dermatology 1999: Study on the TB-500 component: in a rat wound model, thymosin β4 increased re-epithelialization by up to 61% over controls, with more collagen deposition and angiogenesis.
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation - Gastroenterology 2008: Study on the KPV component: KPV enters intestinal epithelial and immune cells via the peptide transporter PepT1, inhibited NF-κB and MAP kinase signaling there and reduced inflammation in two mouse colitis models when given orally.
- Regenerative and Protective Actions of GHK-Cu in the Light of New Gene Data - International Journal of Molecular Sciences 2018: GHK-Cu component.
